Dudediligence.

Inhibikase Therapeutics, Inc

IKTNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24$0.00Sep ’25$0.00Mar ’26$0.00Jun ’26
Net income, by quarter
−$5.8MSep ’24−$12.1MDec ’24−$13.7MMar ’25−$9.9MJun ’25−$11.9MSep ’25−$12.7MDec ’25−$16.4MMar ’26−$19.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$3.1M$123,440$260,501$0.00none on file
Operating income−$14.8M−$18.1M−$20.1M−$28.6M−$52.0M
Net income−$14.8M−$18.1M−$19.0M−$27.5M−$48.3M
Operating cash flow−$14.3M−$17.4M−$18.1M−$19.1M−$27.8M
Free cash flow−$14.3M−$17.6M−$18.1M−$19.1M−$27.8M
Cash$40.8M$7.2M$9.2M$56.5M$178.8M
Debt$248,911$145,836$531,879$110,517$0.00
Shares outstanding25.2M4.2M6.2M69.4M131.7M